60
total announcements
ZYDUSLIFE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹1.12 L Cr
P/E (TTM)
25.1
P/E (Forward)
22.8
EPS (TTM)
₹44.87
52W Low
₹835.50
52W High
₹1,232.10
Dividend Yield
0.09%
Beta
0.37
Price / Book
4.2
Debt / Equity
42.3
Revenue (TTM)
₹28,592 Cr
Gross Margin
72.11%
Operating Margin
16.44%
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange that the USFDA inspection of its manufacturing plant at Moraiya, Ahmedabad, has concluded with 5 observations. The company will work with the USFDA to address these observations promptly.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has announced that the USFDA has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda, for review. This marks a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. The regulatory dossier for FYB206 has also been submitted to Health Canada.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has announced a press release regarding a new post hoc analysis of the Phase 3 EPICS-III trial at ACG 2026, showing greater biochemical response with investigational saroglitazar compared to placebo across geographic subgroups in PBC.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on BSE and NSE.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has partnered with MSN Laboratories Private Limited to launch the first generic version of Adempas (Riociguat Tablets) in the U.S. market, expanding its complex-generics pipeline and commercial reach in the U.S.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about General Updates regarding the extension of the date of closing for the subscription of 50% of the total paid-up equity share capital of Zydus Sunshine Lifesciences (Private) Limited, a 50:50 joint venture with Sunshine Healthcare Lanka Limited.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding a USFDA inspection at its manufacturing plant at SEZ II, Ahmedabad, which concluded with one observation and no data integrity related observations.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange that the USFDA inspection of pharmacovigilance and post-marketing system at its USA office concluded with nil observations.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has published a notice in the Financial Express regarding the loss of share certificates for two shareholders, requesting objections within 7 days to issue duplicate certificates.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about opening a special window for transfer and dematerialization of physical securities purchased or sold prior to April 1, 2019, until February 4, 2027.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about Credit Rating, with CRISIL Ratings Limited reaffirming the credit ratings of various instruments/facilities of the Company.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about its participation in the J.P. Morgan India Conference on September 21, 2026.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about a notice of loss of share certificate published in the Financial Express English and Gujarati Editions.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about General Updates, specifically a settlement agreement with a class of indirect reseller plaintiffs in a US lawsuit, agreeing to pay USD 5.9 million without admitting fault.
Zydus Lifesciences Limited
Zydus Lifesciences Limited held its 31st Annual General Meeting on August 11, 2026, through video conferencing. The meeting was attended by the Chairman, Managing Director, and several directors, as well as the statutory auditors. The Board welcomed a new independent director, Mr. Kulin Lalbhai, who was appointed subject to shareholder approval. The integrated annual report for the year ended March 31, 2026, was also presented, outlining the company's financial performance, ESG initiatives, and commitment to transparency and sustainability.
Zydus Lifesciences Limited
Zydus Lifesciences Limited announced positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH, achieving its primary endpoint of resolution of steatohepatitis with no worsening of fibrosis.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in Gandhinagar, Gujarat.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange about General Updates, disclosing an improvement in its ESG (Environment, Social, and Governance) score from 61 to 66, as per CRISIL Ratings Limited's report dated August 24, 2026.
Zydus Lifesciences Limited
Zydus Lifesciences Limited has made a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Prashant Babubhai Patel, a member of the promoter group.